The European Commission has approved PYRUKYND (mitapivat) for adults living with alpha- or beta-thalassemia across European Union member states. The decision marks a significant milestone because PYRUKYND becomes the only approved medicine in Europe for both transfusion-dependent and non-transfusion-dependent thalassemia patients. The approval also strengthens treatment access for thousands of individuals facing chronic anemia and related complications.
The authorization covers adults experiencing anemia associated with alpha- or beta-thalassemia. Moreover, the medicine received orphan medicinal product designation from European regulators because thalassemia remains a rare and serious inherited blood disorder. PYRUKYND, also known as mitapivat, works as an oral pyruvate kinase activator that targets red blood cell metabolism.
The latest approval expands the global reach of PYRUKYND (mitapivat) because regulators in the United States, Saudi Arabia, and the United Arab Emirates already authorized the therapy. Additionally, the European approval highlights increasing international confidence in the medicine’s clinical value for patients with limited treatment options.
Thalassemia affects hemoglobin production and reduces the body’s ability to transport oxygen effectively. Consequently, patients often experience fatigue, severe anemia, organ complications, and reduced quality of life. Some patients require frequent blood transfusions throughout their lives, while others need occasional transfusion support depending on disease severity.
Clinical experts accepted the approval because treatment options for thalassemia remain limited in many countries. Researchers involved in the program said that “The Phase 3 PYRUKYND (mitapivat) program demonstrated meaningful improvements for patients irrespective of genotype or transfusion status.” They also pointed to the drug’s potential to lessen the burden of disease and improve long-term prognosis.
The European Commission used the results of the ENERGIZE and ENERGIZE-T studies, Phase 3. The global trials assessed PYRUKYND in adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, the efficacy and safety evaluations in both studies were randomized, double-blind, and placebo-controlled.
The ENERGIZE study included 194 adults with non-transfusion-dependent thalassemia. Researchers measured hemoglobin response as the primary endpoint during the treatment period. Meanwhile, the ENERGIZE-T study enrolled 258 adults with transfusion-dependent disease and evaluated reductions in transfusion requirements. According to trial findings, PYRUKYND (mitapivat) showed clinically meaningful improvements across both patient populations.
According to the executives of the company, this is a significant step towards innovating in treating rare diseases. Leaders also noted that PYRUKYND® (mitapivat) now holds approvals across four major markets, reinforcing the medicine’s therapeutic potential. Additionally, the company plans to continue working with its European commercialization partner to expand patient access throughout the region.
An exclusive commercialization agreement signed in 2025 supports distribution and commercialization activities for PYRUKYND® (mitapivat) across the European Economic Area, Switzerland, and the United Kingdom. The collaboration aims to improve access to rare disease therapies across Europe through specialized pharmaceutical networks.
Patient advocacy organizations also praised the European Commission’s decision because many thalassemia patients continue facing lifelong treatment challenges. Advocacy leaders said the community has waited years for convenient and effective oral treatment options. Therefore, the approval of PYRUKYND (mitapivat) may bring new hope to people living with debilitating symptoms and frequent transfusion regimens.
The estimated number of children and adults living with thalassemia in the five largest countries in the United States and Europe is 18,000-23,000. The disease can decrease life expectancy and increase health care complications, and physicians are still looking for therapies that increase both clinical outcomes and quality of life.
In Europe, PYRUKYND was already approved in 2022 for adults who have pyruvate kinase deficiency. With the approval, the medicine became the first disease-modifying agent for that rare condition. Ever since, scientists have kept investigating other uses of the medicine, especially in other hematologic conditions like thalassemia and sickle cell disease.
The European Medicines Agency’s Committee for Medicinal Products for Human Use had already issued a positive recommendation supporting the thalassemia indication before the Commission finalized authorization. So the latest decision was viewed by industry analysts as an expected, but significant, regulatory development for the company and the rare disease market in general.
Healthcare experts believe PYRUKYND (mitapivat) has the potential to change the way doctors manage thalassemia, as the drug provides an oral treatment option for a wide range of patients. Additionally, the approval signals increasing momentum for new approaches to treating the disease based on its underlying mechanisms, rather than just supportive care measures.
